Effects of metformin on retinoblastoma growth in vitro and in vivo

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2311-2324

  Brodowska, Katarzyna ^a   Theodoropoulou, Sofia ^a   Hörste, Melissa Meyer Zu ^a   Paschalis, Eleftherios I ^a   Takeuchi, Kimio ^a   Scott, Gordon ^a   Ramsey, David J ^a   Kiernan, Elizabeth ^a   Hoang, Mien ^a   Cichy, Joanna ^b   Miller, Joan W ^a   Gragoudas, Evangelos S ^a   Vavvas, Demetrios G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Apoptosis; Autophagy; Cyclin; Proliferation; Toxicity

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL; APOPTOSIS; AUTOPHAGY; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; PATHOLOGY; RETINOBLASTOMA;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; AUTOPHAGY; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METFORMIN; MICE; RETINOBLASTOMA; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907699881     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2650     Document Type: Article

References (80)

1. Broaddus E, Topham A and Singh AD: Incidence of retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93:21-23, 2009.
2. Rodriguez-Galindo CC, Wilson M W M, Haik B G B, et al: Treatment of metastatic retinoblastoma. Ophthalmology 110:1237-1240, 2003.
3. Roarty JD, McLean IW and Zimmerman LE: Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 95:1583-1587, 1988.
4. Shaw RJ, Lamia KA, Vasquez D, et al: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646, 2005.
5. Marr BP, Hung C, Gobin YP, Dunkel IJ, Brodie SE and Abramson DH: Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy. Arch Ophthalmol 130:180-185, 2012.
6. Liu J, Li M, Song B, et al: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 31:264-270, 2013.
7. Bianciotto C, Shields CL, Iturralde JC, Sarici A, Jabbour P and Shields JA: Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology 119:843-849, 2012.
8. Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS and Reddy MA: Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology 119:611-616, 2012.
9. Miyano-Kurosaki N, Kurosaki K, Hayashi M, et al: 2.aminophenoxazine-3.one suppresses the growth of mouse malignant melanoma B16 cells transplanted into C57BL/6Cr Slc mice. Biol Pharm Bull 29:2197-2201, 2006.
10. Ghassemi F and Shields CL: Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol 130:1268-1271, 2012.
11. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42:922-933, 2012.
12. Munier FL, Gaillard M-C, Balmer A, et al: Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 96:1078-1083, 2012.
13. Shields C L C, Honavar S G S, Shields J A J, Demirci HH, Meadows A T A and Naduvilath T J T: Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 120:460-464, 2002.
14. Shields CL, Shelil A, Cater J, Meadows AT and Shields JA: Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 121:1571-1576, 2003.
15. Sussman DA, Escalona-Benz E, Benz MS, et al: Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Arch Ophthalmol 121:979-984, 2003.
16. Schefler AC, Cicciarelli N, Feuer W, Toledano S and Murray TG: Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Opthalmology 114:162-169, 2007.
17. Shields CL: Forget-me-nots in the care of children with retinoblastoma. Semin Ophthalmol 23:324-334, 2009.
18. Shields CL, Palamar M, Sharma P, et al: Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch Ophthalmol 127:282-290, 2009.
19. Benz MS, Scott IU, Murray TG, Kramer D and Toledano S: Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol 118:577-578, 2000.
20. Nishimura S, Sato T, Ueda H and Ueda K: Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol 19:4182-4183, 2001.
21. Stumvoll M, Nurjhan N, Perriello G, Dailey G and Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995.
22. Zhou G, Myers R, Li Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001.
23. Hundal HS, Ramlal T, Reyes R, Leiter LA and Klip A: Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 131:1165-1173, 1992.
24. Sahra IB, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576-3586, 2008.
25. Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53.deficient tumor cell growth. Cancer Res 67:6745-6752, 2007.
26. + human breast cancer xenografts. Oncotarget 3:395-398, 2012.
27. Tomic T, Botton T, Cerezo M, et al: Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2: e199, 2011.
28. Kato K, Gong J, Iwama H, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 11:549-560, 2012.
29. Martin MJ, Hayward R, Viros A and Marais R: Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov 2:344-355, 2012.
30. Phoenix KN, Vumbaca F and Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113:101-111, 2009.
31. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273, 2006.
32. Zhuang Y and Miskimins WK: Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3:18, 2008.
33. Towler MC and Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328-341, 2007.
34. Vijg J and Campisi J: Puzzles, promises and a cure for ageing. Nature 454:1065-1071, 2008.
35. Moruno-Manchon JF, Perez-Jimenez E and Knecht E: Glucose induces autophagy under starvation conditions by a p38 MAPK-dependent pathway. Biochem J 449:497-506, 2013.
36. Hardie DG: The LKB1-AMPK pathway-friend or foe in cancer? Cancer Cell 23:131-142, 2013.
37. Doyle A, Zhang G, Abdel Fattah EA, Eissa NT and Li YP: Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J 25:99-110, 2011.
38. Matsuzawa T, Kim B-H, Shenoy AR, Kamitani S, Miyake M and Macmicking JD: IFN.γ elicits macrophage autophagy via the p38 MAPK signaling pathway. J Immunol 189:813-818, 2012.
39. Webber JL and Tooze SA: Coordinated regulation of autophagy by p38alpha MAPK through mAtg9 and p38IP. EMBO J 29:27-40, 2010.
40. Thyagarajan A, Jedinak A, Nguyen H, et al: Triterpenes from Ganoderma Lucidum induce autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase (p38 MAPK). Nutr Cancer 62:630-640, 2010.
41. Osborne CK, Bolan G, Monaco ME and Lippman ME: Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA 73:4536-4540, 1976.
42. Metformin insert: 1-6, 2009. Distributed by: Bristol-Myers Squibb Company Princeton, NJ 08543, USA. http://packageinserts-bms.com/pi/pi-glucophage-xr.pdf
43. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ and Dennis PA: Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metabol 24:469-480, 2013.
44. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, et al: In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 668:373-382, 2011.
45. Hadad SM, Appleyard V and Thompson AM: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 114:391-399, 2009.
46. Dool CJ, Mashhedi H, Zakikhani M, et al: IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocr Relat Cancer 18:699-709, 2011.
47. Wilcock C and Bailey CJ: Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24:49-57, 1994.
48. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305, 2005.
49. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A and Decensi A: Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18:701-705, 2009.
50. Noto H, Goto A, Tsujimoto T and Noda M: Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 7: e33411, 2012.
51. Becker C, Meier CR, Jick SS and Bodmer M: Case-control analysis on metformin and cancer of the esophagus. Cancer Causes Control 24:1763-1770, 2013.
52. Becker C, Jick SS, Meier CR and Bodmer M: Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol Oncol 129:565-569, 2013.
53. Bodmer M, Becker C, Jick SS and Meier CR: Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer 78:133-137, 2012.
54. Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 21:280-286, 2012.
55. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE and Bergstralh EJ: Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 32:43-e1-7, 2013.
56. Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 107:620-626, 2012.
57. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A and Sasidhar M: The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 12:410, 2012.
58. Bodmer M, Becker C, Meier C, Jick SS and Meier CR: Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 123:200-204, 2011.
59. Bodmer M, Meier C, Krahenbuhl S, Jick SS and Meier CR: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304-1308, 2010.
60. Tomimoto A, Endo H, Sugiyama M, et al: Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Science 99:2136-2141, 2008.
61. Theodoropoulou S, Kolovou PE, Morizane Y, et al: Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J 24:2620-2630, 2010.
62. Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280:39582-39593, 2005.
63. Inoki KK, Zhu TT and Guan K-LK: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590, 2003.
64. Cheng S W Y, Fryer L G D, Carling D and Shepherd PR: Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 279:15719-15722, 2004.
65. Sarbassov DD, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 17:596-603, 2005.
66. Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726-734, 2005.
67. Hawley SA, Gadalla AE, Olsen GS and Hardie DG: The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420-2425, 2002.
68. Kalender A, Selvaraj A, Kim SY, et al: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11:390-401, 2010.
69. Liu B, Fan Z, Edgerton SM, et al: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8:2031-2040, 2009.
70. Li C, Liu V W S, Chan DW, Yao KM and Ngan H Y S: LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer 22:15-22, 2012.
71. Capano M and Crompton M: Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem J 395:57-64, 2006.
72. Xi X, Han J and Zhang JZ: Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem 276:41029-41034, 2001.
73. Wurth R, Pattarozzi A, Gatti M, et al: Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle 12:145-156, 2013.
74. Bao B, Wang Z, Ali S, et al: Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prevent Res 5:355-364, 2012.
75. Ben Sahra I, Regazzetti C, Robert G, et al: Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71:4366-4372, 2011.
76. Soranna D, Scotti L, Zambon A, et al: Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17:813-822, 2012.
77. Bost F, Sahra IB, Le Marchand-Brustel Y and Tanti JF: Metformin and cancer therapy. Curr Opin Oncol 24:103-108, 2012.
78. Iliopoulos D, Hirsch HA and Struhl K: Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71:3196-3201, 2011.
79. Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507-7511, 2009.
80. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9:1057-1064, 2010.